SCHEMBL24257787

SCHEMBL24257787

COC(=O)CNC(=O)c1ncc(-c2cnc(-c3ccccc3)o2)c(C)c1OCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 12/20 0.42
VEGFA P15692 4/20 0.41
FLT1 P17948 4/20 0.41
EGLN3 Q9H6Z9 3/20 0.41
L3MBTL1 Q9Y468 2/20 0.38
MAPT P10636 2/20 0.38
RAB9A P51151 2/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 1/20 0.38
TP53 P04637 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257563 0.86 EGLN1 (0.47) EGLN1VEGFAFLT1EGLN3L3MBTL1
SCHEMBL24257561 0.85 RAB9A (0.41) L3MBTL1MAPTRAB9AKDM4ENPC1
SCHEMBL24257688 0.82 EGLN1 (0.47) EGLN1VEGFAFLT1EGLN3L3MBTL1
SCHEMBL30453334 0.82 EGLN1 (0.47) EGLN1VEGFAFLT1EGLN3L3MBTL1
SCHEMBL30546873 0.82 EGLN1 (0.47) EGLN1VEGFAFLT1EGLN3L3MBTL1
SCHEMBL24257565 0.77 EGLN1 (0.49) EGLN1VEGFAFLT1EGLN3
SCHEMBL30453137 0.76 ALDH1A1 (0.48) L3MBTL1MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL30546860 0.76 ALDH1A1 (0.48) L3MBTL1MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL24257514 0.76 ALDH1A1 (0.48) L3MBTL1MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL24257686 0.75 GAA (0.48) EGLN1L3MBTL1MAPTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
EP-4196466-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE Akebia Therapeutics Inc. (US) 2023-06-21 EP disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 EGLN1 19/4885VEGFA 1862/4885FLT1 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.